Cytoreductive Surgery and Hyperthermic Chemotherapy Role in Peritoneal Carcinomatosis Treatment
Main Article Content
Abstract
The aim of this article is to provide a review of some current therapeutic strategies for patients with peritoneal carcinomatosis (PC), which historically has been considered a terminal condition, only amenable to palliative care, and occasionally systemic chemotherapy alone with poor response and lower average survival. The combination of cytoreductive surgery (CRS), which involves peritonectomy and multivisceral resections and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is a relatively new intraperitoneal treatment of microscopic residual disease concept. The indication of this method has been extended progressively to highly selected patients with PC and it is based in several phase III studies, which concluded that it is possible to obtain sufficient cytoreduction. However, until now there is some consensus based on evidence, in which HIPEC would be indicated in patients with peritoneal PC originated in pseudomyxoma, peritoneal mesothelioma and colorectal cancer; and CP from another source, depending on each particularcase.
References
Al-Shammaa, H. A.; Li, Y. & Yonemura, Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J. Gastroenterol., 14(8):1159-66,2008.
Benoit, L.; Cheynel, N.; Ortega-Deballon, P.; Giacomo, G. D.; Chauffert, B. & Rat, P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann. Surg. Oncol., 15(2):542-6, 2008.
Brücher, B. L.; Piso, P.; Verwaal, V.; Esquivel, J.; Derraco, M.; Yonemura, Y.; Gonzalez-Moreno, S.; Pelz, J.; Königsrainer, A.; Ströhlein, M.; Levine, E. A.; Morris, D.; Bartlett, D.; Glehen, O.; Garofalo, A. & Nissan, A. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest., 30(3):209-24, 2012.
Cao, C.; Yan, T. D.; Morris, D. L.; van der Speeten, K.; Laurberg, S.; Glehen, O.; Link, K.; Piso, P.; Tentes, A. A.; Deraco, M.; Larsen, S. G.; Kecmanovic, D.; Bayón, L. G.; Melero, J. T.; González-Moreno, S.; Mahteme, H.; Gertsch, P.; Moran, B.; Esquivel, J.; Alexander, R.; Levine, E. A. & Sugarbaker, P. H. Prospective Registry On Mesothelioma Peritonei Treatment (PROMPT): study design and rationale. Tumori, 98(1):166-71. 2012.
Chua, T. C.; Pelz, J. O. & Morris, D. L. Surgery for colorectal peritoneal carcinomatosis. Scand. J. Gastroenterol., 47(3):277-85, 2012a.
Chua, T. C.; Moran, B. J.; Sugarbaker, P. H.; Levine, E. A.; Glehen, O.; Gilly, F. N.; Baratti, D.; Deraco, M.; Elias, D.; Sardi, A.; Liauw, W.; Yan, T. D.; Barrios, P.; Gómez Portilla, A.; de Hingh, I. H.; Ceelen, W. P.; Pelz, J. O.; Piso, P.; González-Moreno, S.; Van Der Speeten, K. & Morris, D. L. Earlyand long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J. Clin. Oncol., 30(20):2449-56, 2012b.
de Mestier, L.; Lardière-Deguelte, S.; Brixi, H.; O'Toole, D.; Ruszniewski, P.; Cadiot, G. & Kianmanesh, R. Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors. Neuroendocrinology, 101(2):105-11, 2015.
Farré Alegre, J.; Bretcha Boix, P.; Martín, M. L.; Sureda, M. & Brugarolas, A. Carcinomatosis peritoneal. Quimioterapia intraperitoneal con hipertermia. Oncología (Barc.), 27(4):134-8, 2004.
Glockzin, G. & Piso, P. Current status and future directions in gastric cancer with peritoneal dissemination. Surg. Oncol. Clin. N. Am., 21(4):625-33, 2012.
Gómez Portilla, A.; Cendoya, I.; López de Tejeda, I.; Olabarría, I.; Magrach, L.; Martínez de Lecea, C.; Gil, A.; Valdovinos, M.; Larrabide, I.; Ruiz de Alegría, N.; Fernández, J. L.; Cachorro, I.; Contreras, M. C.; Castañeda, J.; Uriarte, A.; Boado, M. V.; Urturi, J. A. & Ulibarrena, M. A. Bases y fundamentos del tratamiento de la carcinomatosis peritoneal por cáncer colorrectal. Revisión actual y puesta al día. Cir. Esp., 77(1):6-17, 2005.
Gómez Portilla, A. Peritoneal carcinomatosis. Peritoneal carcinomatosis. Ten years of applying the new combined triple therapy. Personal experience. Cir. Esp., 82(6):346-51, 2007.
González-Moreno, S.; González-Bayón, L. & OrtegaPérez, G. Hyperthermic intraperitoneal chemotherapy: methodology and safety considerations. Surg. Oncol. Clin. N. Am., 21(4):543-57, 2012.
Guerrero Zotano, A.; Aparicio Urtasun, J.; Pellín Ariño, L.; Molina Saera, J.; Palomar Abad, L. & Ponce Lorenzo, J. Carcinomatosis peritoneal por tumor apendicular. Oncología (Barc.), 28(4):35-9, 2005.
Jacquet, P. & Sugarbaker, P. H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res., 82:359-74, 1996.
Koppe, M. J.; Boerman, O. C.; Oyen, W. J. & Bleichrodt, R. P. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann. Surg., 243(2):212-22, 2006.
Kulu, Y.; Müller-Stich, B.; Büchler, M. W. & Ulrich, A. Surgical treatment of peritoneal carcinomatosis: current treatment modalities. Langenbecks Arch. Surg., 399(1):41-53, 2014.
López-Basave, H. N.; Morales-Vásquez, F.; Ortiz, K. L.; Méndez Herrera, C. & Ruiz-Molina, J. M. Citorreducción e HIPEC en carcinomatosis peritoneal. Experiencia del Instituto Nacional de Cancerología de México. Cir. Gen., 36(3):138-44, 2014.
Losa, F.; Barrios, P.; Salazar, R.; Torres-Melero, J.; Benavides, M.; Massuti, T.; Ramos, I. & Aranda, E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin. Transl. Oncol., 16(2):128-40, 2014.
Michalakis, J.; Georgatos, S. D.; de Bree, E.; Polioudaki, H.; Romanos, J.; Georgoulias, V.; Tsiftsis, D. D. & Theodoropoulos, P. A. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann. Surg. Oncol., 14(3):1220-8, 2007.
Morgan, R. J. Jr.; Synold, T. W.; Xi, B.; Lim, D.; Shibata, S.; Margolin, K.; Schwarz, R. E.; Leong, L.; Somlo, G., Twardowski, P.; Yen, Y.; Chow, W.; Tetef, M.; Lin, P.; Paz, B.; Koczywas, M.; Wagman, L.; Chu, D.; Frankel, P.; Stalter, S. & Doroshow, J. H. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin. Cancer Res., 13(4):1232-7, 2007.
Nadler, A.; McCart, J. A. & Govindarajan, A. Peritoneal carcinomatosis from colon cancer: A systematic review of the data for cytoreduction and intraperitoneal chemotherapy. Clin. Colon Rectal Surg., 28(4):234-46, 2015.
Roviello, F.; Caruso, S.; Marrelli, D.; Pedrazzani, C.; Neri, A.; De Stefano, A. & Pinto, E. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg. Oncol., 20(1):e38-54, 2011.
Spiliotis, J. D.; Halkia, E. A. & Efstathiou, E. Peritoneal carcinomatosis 2011; it's about time for chemosurgery. J. BUON, 16(3):400-8, 2011.
Stewart, J. H. 4th; Shen, P. & Levine, E. A. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann. Surg. Oncol., 12(10):765- 77, 2005.
Sugarbaker, P. H.; Cunliffe, W. J.; Belliveau, J.; de Bruijn, E. A.; Graves, T.; Mullins, R. E. & Schlag, P. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin. Oncol., 16(4 Suppl. 6):83-97, 1989.
Sugarbaker, P. H.; Mora, J. T.; Carmignani, P.; Stuart, O. A. & Yoo, D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist, 10(2):112-22, 2005.
Sugarbaker, P. H. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol., 7(1):69-76, 2006.
Yonemura, Y.; Endou, Y.; Fujita, H.; Fushida, S.; Bandou, E.; Taniguchi, K.; Miwa, K.; Sugiyama, K. & Sasaki, T. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer, 3(2):63-70, 2000.
Yonemura, Y.; Bandou, E.; Kinoshita, K.; Kawamura, T.; Takahashi, S.; Endou, Y. & Sasaki, T. Effective therapy for peritoneal dissemination in gastric cancer. Surg. Oncol. Clin. N. Am., 12(3):635-48,2003.
Yonemura, Y.; Bandou, E.; Kawamura, T.; Endou, Y. & Sasaki, T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur. J. Surg. Oncol., 32(6):602-6, 2006.
Weber, T.; Roitman, M. & Link, K. H. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Clin. Colorectal Cancer, 11(3):167-76, 2012.
Valle, M.; Federici, O. & Garofalo, A. Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg. Oncol. Clin. N. Am., 21(4):515-31, 2012.